MingMed Biotech Joins Queue of Revenue-less Drug Startups Seeking IPO Cash
It has seven drugs under development but none on the market yet. But one thing MingMed Biotech has plenty of is losses Key Takeaways: With no drug revenues and growing…
RELATED ARTICLES
-
AstraZeneca pays hefty price for Chinese weight-loss drug
AZN.US
-
Kintor shares plunge after hair-loss drug flops in clinical trials
9939.HK
-
Akeso marks profit milestone with swift rights issue
9926.HK
- InSilico seeks IPO boost to get AI drugs over the line
- HighTide Therapeutics places big IPO bet on “affluenza” drug
-
Drug maker Junshi seeks Swiss cure for cash woes
1877.HK 688150.SHG
-
HBM gets health boost from drug licensing deals
2142.HK
Discover hidden China stock gems in our weekly newsletter